MASH Treatment Market Intensifies with New Therapies

The market for treatments for Metabolic Dysfunction-Associated Steatohepatitis (MASH) is moving into a significant commercialization wave. Success is increasingly defined not only by clinical efficacy but also by improvements in liver fibrosis, metabolic benefits, safety profiles, diagnostic capabilities, payer acceptance, and treatment accessibility.

In the United States, Rezdiffra (Madrigal Pharmaceuticals) and Wegovy (Novo Nordisk) are currently the primary approved treatments for adults with non-cirrhotic MASH and moderate-to-advanced fibrosis. Rezdiffra has established early market leadership as the first approved MASH therapy, achieving US$958.4 million in net product sales in 2025. However, the approval of Novo Nordisk's Wegovy has reshaped the competitive landscape by introducing a GLP-1-based metabolic therapy directly into the MASH arena, intensifying competition around weight loss, diabetes overlap, and cardiometabolic benefits.

Future competition will likely be shaped by companies demonstrating stronger fibrosis regression, durable MASH resolution, broader metabolic improvements, and easier patient identification. Large pharmaceutical interest is accelerating, with several new candidates in development targeting various mechanisms, including thyroid hormone receptor beta agonists and FGF21 analogues.

MASH is a progressive metabolic liver disease characterized by fat accumulation, inflammation, and fibrosis, strongly associated with obesity and type 2 diabetes. Globally, an estimated over 250 million people live with MASH, with a significant portion remaining undiagnosed. Growth in the treatment market is supported by diagnostic advancements and emerging targeted therapies, though low diagnosis rates and payer coverage limitations may temper faster adoption.